Twitter

Chordate Medical Receives Trademark Registration for Ozilia® in the United States

Chordate Medical Holding AB announces that the United States Patent and Trademark Office (USPTO) has decided to grant registration of Chordate’s trademark OZILIA.

This marks the fifth national registration of OZILIA under the Madrid Protocol, meaning that the trademark is now registered in the U.S., Israel, Japan, China, and the United Kingdom. A corresponding application for registration in Brazil is currently under review. Since 2023, the trademark has also been registered in the European Union.

“The OZILIA trademark has been well received by the market, and protecting it through registrations is part of our IP strategy aimed at building long-term value in the company and making the business more attractive to potential buyers,” says Anders Weilandt, CEO of Chordate Medical.

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia®, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Bergs Securities AB.

Press releases

Chordate Medical AB

Färögatan 33
SE-164 51 Kista
Sweden
For visits: floor B31

Delivery: Hanstavägen 31, 164 53 Kista

Privacy policy

Twitter